Novartis AG (NVSEF)
163.60
+5.99
(+3.80%)
USD |
OTCM |
Aug 24, 16:00
Novartis EPS Diluted (Quarterly) : 1.705 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.705 |
| March 31, 2026 | 1.647 |
| December 31, 2025 | 1.249 |
| September 30, 2025 | 2.025 |
| June 30, 2025 | 2.062 |
| March 31, 2025 | 1.822 |
| December 31, 2024 | 1.406 |
| September 30, 2024 | 1.573 |
| June 30, 2024 | 1.586 |
| March 31, 2024 | 1.307 |
| December 31, 2023 | 4.106 |
| September 30, 2023 | 0.8487 |
| June 30, 2023 | 1.106 |
| March 31, 2023 | 1.082 |
| December 31, 2022 | 0.6819 |
| September 30, 2022 | 0.7216 |
| June 30, 2022 | 0.7662 |
| March 31, 2022 | 0.9933 |
| December 31, 2021 | 7.238 |
| September 30, 2021 | 1.224 |
| June 30, 2021 | 1.283 |
| March 31, 2021 | 0.9091 |
| December 31, 2020 | 0.9176 |
| September 30, 2020 | 0.8406 |
| June 30, 2020 | 0.8103 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.9494 |
| December 31, 2019 | 0.4908 |
| September 30, 2019 | 0.889 |
| June 30, 2019 | 2.914 |
| March 31, 2019 | 0.755 |
| December 31, 2018 | 0.5116 |
| September 30, 2018 | 0.6942 |
| June 30, 2018 | 3.311 |
| March 31, 2018 | 0.8628 |
| December 31, 2017 | 0.84 |
| September 30, 2017 | 0.88 |
| June 30, 2017 | 0.83 |
| March 31, 2017 | 0.70 |
| December 31, 2016 | 0.40 |
| September 30, 2016 | 0.81 |
| June 30, 2016 | 0.75 |
| March 31, 2016 | 0.84 |
| December 31, 2015 | 0.44 |
| September 30, 2015 | 0.77 |
| June 30, 2015 | 0.75 |
| March 31, 2015 | 5.32 |
| December 31, 2014 | 0.61 |
| September 30, 2014 | 1.31 |
| June 30, 2014 | 1.03 |
| March 31, 2014 | 1.19 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | -2.211 |
| Oculis Holding AG | -0.2059 |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 3.257B |
| Revenue (Quarterly) | 14.41B |
| Total Expenses (Quarterly) | 11.14B |
| Enterprise Value | 341.21B |
| Gross Profit Margin (Quarterly) | 74.47% |
| Profit Margin (Quarterly) | 22.61% |
| Earnings Yield | 4.05% |
| Operating Earnings Yield | 5.14% |
| Normalized Earnings Yield | 4.347 |